The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Yi-Bin ChenDuring The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the AML Hub was pleased to speak with Yi-Bin Chen, Massachusetts General hospital, Boston, US. We asked, Is sorafenib the new standard maintenance treatment for FLT3 mutant AML?
Is sorafenib the new standard maintenance treatment for FLT3 mutant AML?
Chen begins by highlighting advances and describing sorafenib as the new standard of care after allo-SCT in FLT3 mutated AML. He outlines the benefits of allo-HSCT as a consolidation therapy as well as studies on maintenance therapies after transplant using FLT3 inhibitors. Finally, he discusses differences in the availability and toxicity of these agents e.g. midostatorin and gilteritinib.